Mosaiques Diagnostics
Mosaiques Diagnostics & Therapeutics AG, based in Hannover, Germany, specializes in early and reliable disease detection through clinical proteome analysis enabling personalized medicine and drug development. The company uses diagnostic peptide patterns from proteins and peptides in body fluids like urine and bile, employing proprietary CE-MS technology for fast, high-resolution analysis. Their technology identifies up to 6,000 proteins and peptides to generate disease-specific biomarker patterns for early diagnosis of cardiovascular, kidney, biliary, urogenital diseases, and cancers. Mosaiques has a strong scientific foundation with over 400 publications and collaborations with 85+ global research institutions. Their diagnostic tests for diseases such as chronic kidney disease, heart failure, prostate and bladder cancer, and cholangiocarcinoma are marketed in Germany, with plans for European expansion. They also develop AI-driven drug discovery pipelines, particularly in oncology, to repurpose drugs based on multi-omics data integration. Their business model includes providing clinical proteomics services and diagnostic products through subsidiaries like protexam GmbH, targeting academic institutions, pharmaceutical companies, and healthcare providers.
Mosaiques Diagnostics
Mosaiques Diagnostics & Therapeutics AG, based in Hannover, Germany, specializes in early and reliable disease detection through clinical proteome analysis enabling personalized medicine and drug development. The company uses diagnostic peptide patterns from proteins and peptides in body fluids like urine and bile, employing proprietary CE-MS technology for fast, high-resolution analysis. Their technology identifies up to 6,000 proteins and peptides to generate disease-specific biomarker patterns for early diagnosis of cardiovascular, kidney, biliary, urogenital diseases, and cancers. Mosaiques has a strong scientific foundation with over 400 publications and collaborations with 85+ global research institutions. Their diagnostic tests for diseases such as chronic kidney disease, heart failure, prostate and bladder cancer, and cholangiocarcinoma are marketed in Germany, with plans for European expansion. They also develop AI-driven drug discovery pipelines, particularly in oncology, to repurpose drugs based on multi-omics data integration. Their business model includes providing clinical proteomics services and diagnostic products through subsidiaries like protexam GmbH, targeting academic institutions, pharmaceutical companies, and healthcare providers.